Document Detail

Evaluation of in vitro in vivo correlations for dry powder inhaler delivery using artificial neural networks.
MedLine Citation:
PMID:  18035525     Owner:  NLM     Status:  MEDLINE    
The aim of these experiments was to investigate the use of artificial neural networks (ANNs) for generating models able to predict the relative lung bioavailability and clinical effect of salbutamol when delivered to healthy volunteers and asthmatic patients from dry powder inhalers (DPIs). ANN software was used to model in vitro, demographic and in vivo data from human subjects for four different DPI formulations containing salbutamol sulfate. In 12 volunteers, a model linking the in vitro aerodynamic characteristics of the emitted dose and volunteer body surface area with the urinary excretion of drug and its metabolite in the 24h period after inhalation was established. In 11 mild asthmatics, a predictive model correlating in vitro data, baseline lung function, body surface area and age with post-treatment improvements in forced expiratory volume in 1s (FEV1) was also generated. Models validated using unseen data from individual subjects receiving the different DPI formulations were shown to give predictions of in vivo performance. The squared correlation coefficients (R2) for plots comparing predicted and observed in vivo outcomes were 0.83 and 0.84 for urinary excretion and lung function data, respectively. It can therefore be concluded that ANN models have the potential to predict the in vivo performance of DPIs in individual subjects.
Marcel de Matas; Qun Shao; Catherine H Richardson; Henry Chrystyn
Related Documents :
20572455 - Selecting the most relevant variables for anaerobic digestion imbalances: two case stud...
18035525 - Evaluation of in vitro in vivo correlations for dry powder inhaler delivery using artif...
11718425 - A new algorithm to design compact two-hidden-layer artificial neural networks.
12849905 - Neural network in hematopoietic malignancies.
8486795 - The measurement and mismeasurement of ophidiophobia in analogue research: a procedural ...
24167155 - Telling metabolic stories to explore metabolomics data: a case study on the yeast respo...
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2007-10-17
Journal Detail:
Title:  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences     Volume:  33     ISSN:  0928-0987     ISO Abbreviation:  Eur J Pharm Sci     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2007-12-17     Completed Date:  2008-05-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9317982     Medline TA:  Eur J Pharm Sci     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  80-90     Citation Subset:  IM    
Institute of Pharmaceutical Innovation, University of Bradford, Bradford BD7 1DP, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Albuterol / administration & dosage*,  pharmacokinetics,  therapeutic use
Asthma / drug therapy,  pathology,  physiopathology
Biological Availability
Bronchodilator Agents / administration & dosage,  pharmacokinetics,  therapeutic use
Drug Delivery Systems / instrumentation,  methods*
Lung / metabolism,  pathology,  physiopathology
Middle Aged
Nebulizers and Vaporizers*
Neural Networks (Computer)*
Particle Size
Peak Expiratory Flow Rate
Powders / chemistry
Severity of Illness Index
Technology, Pharmaceutical / instrumentation,  methods
Time Factors
Reg. No./Substance:
0/Bronchodilator Agents; 0/Powders; 18559-94-9/Albuterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bile salt-phospholipid aggregation at submicellar concentrations.
Next Document:  How do high-level specifications of the brain relate to variational approaches?